Mauro Cives

List of Publications by Year
in descending order

36 papers	1,509 citations	471371 17 h-index	345118 36 g-index
36 all docs	36 docs citations	36 times ranked	2310 citing authors

#	Article	IF	Citations
1	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	2.8	21
2	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. Neuroendocrinology, 2021, 111, 207-216.	1.2	13
3	Sensitivity and Specificity of the NETest: A Validation Study. Neuroendocrinology, 2021, 111, 580-585.	1.2	6
4	Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is â‰¥10%?. Oncologist, 2021, 26, 294-301.	1.9	17
5	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. World Journal of Gastroenterology, 2021, 27, 976-989.	1.4	3
6	Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Current Treatment Options in Oncology, 2021, 22, 73.	1.3	6
7	The psychological impact of COVIDâ€19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability. Journal of Neuroendocrinology, 2021, 33, e13041.	1.2	3
8	Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treatment Reviews, 2021, 100, 102288.	3.4	9
9	A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 377-383.	1.2	15
10	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. International Journal of Molecular Sciences, 2020, 21, 52.	1.8	38
11	Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. Journal of Clinical Medicine, 2020, 9, 3655.	1.0	23
12	Non-Melanoma Skin Cancers: Biological and Clinical Features. International Journal of Molecular Sciences, 2020, 21, 5394.	1.8	83
13	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) â‰¥2 cm: Study Protocol for a Prospective Observational Study. Frontiers in Medicine, 2020, 7, 598438.	1.2	33
14	Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 3022.	1.8	11
15	Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. Translational Gastroenterology and Hepatology, 2020, 5, 54-54.	1.5	29
16	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 72.	1.3	7
17	The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology, 2019, 109, 83-99.	1.2	87
18	Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 489.	3.4	2

#	Article	IF	Citations
19	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Frontiers in Oncology, 2019, 9, 1148.	1.3	90
20	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Scientific Reports, 2019, 9, 18614.	1.6	26
21	Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours. British Journal of Cancer, 2019, 120, 294-300.	2.9	25
22	Local treatment for focal progression in metastatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 405-409.	1.6	10
23	The management of refractory carcinoid syndrome: challenges and opportunities ahead. Journal of Medical Economics, 2018, 21, 241-243.	1.0	1
24	SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand. Oncotarget, 2018, 9, 25355-25382.	0.8	34
25	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget, 2018, 9, 20826-20837.	0.8	97
26	Gastroenteropancreatic Neuroendocrine Tumors. Ca-A Cancer Journal for Clinicians, 2018, 68, 471-487.	157.7	378
27	Radionuclide Therapy for Neuroendocrine Tumors. Current Oncology Reports, 2017, 19, 9.	1.8	113
28	Osteotropism of neuroendocrine tumors: role of the CXCL12/CXCR4 pathway in promoting EMT in vitro. Oncotarget, 2017, 8, 22534-22549.	0.8	21
29	Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	1.9	62
30	Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition. Neuroendocrinology, 2016, 103, 321-334.	1.2	19
31	Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations. BMC Cancer, 2016, 16, 87.	1.1	20
32	NETs: organ-related epigenetic derangements and potential clinical applications. Oncotarget, 2016, 7, 57414-57429.	0.8	23
33	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer, 2015, 15, 692.	1.1	16
34	Erdheimâ€“Chester disease: A systematic review. Critical Reviews in Oncology/Hematology, 2015, 95, 1-11.	2.0	153
35	An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. Experimental Hematology, 2014, 42, 897-908.e1.	0.2	13
36	Cell Fusion in Myeloma Marrow Microenvironment: Role in Tumor Progression. Critical Reviews in Oncogenesis, 2013, 18, 75-95.	0.2	2